JEFFREY PLUMER
GENERAL COUNSEL
EVOLUS INC.
WHY: Oversees all legal and compliance matters at Newport Beach medical aesthetics firm Evolus (Nasdaq: EOLS); led company through 2018 initial public offering, launching its flagship neurotoxin product Jeuveau and expanding distribution internationally.
IN THE NEWS: 2024 winner at Business Journal’s General Counsel Awards; Plumer will deal with different regulation for medical devices instead of pharmaceuticals due to the new dermal fillers product Evolysse in 2025.
NOTABLE: First worked as outside counsel for Evolus parent Alphaeon Corp. then went in-house before IPO; was VP of legal and corporate secretary for six years until appointed GC in 2020; Evolus now valued at $933M as of February and is targeting $700M in revenue by 2028.
QUOTABLE: “We want to be one of those Orange County public companies that’s here to stay.”
